<DOC>
	<DOCNO>NCT00566332</DOCNO>
	<brief_summary>Waldenström 's macroglobulinaemia ( WM ) lymphoproliferative disorder characterize monoclonal IgM paraprotein morphological evidence lymphoplasmacytic lymphoma : cell IgM+ , IgD+ , CD19+ CD20+ usually CD5- , CD10- CD23- . The treatment efficacy difficult assess lack clear diagnostic criterion , good response criterion , randomize trial . The actual treatment Chlorambucil , alkylating agent . A purine analogue Fludarabine proven efficacy 30 % 80 % first line therapy This study phase II b open , prospective , international multicenter trial ( England , Dr Johnson , Dr Catovsky , Australia : Dr Seymour ) promote French Cooperative Group Chronic Lymphoid Leukemia untreated WM , closely related disorder ( Lymphoplasmacytic lymphoma splenic marginal zone lymphoma ) . 366 patient must include , among 180 patient France . Patients stratify accord lymphoproliferative disorder . The patient receive Chlorambucil oral route 10 day every 28 day ( 12 cycle ) ( 8 MG/M² , 6 MG/M² patient 75 year old ) Fludarabine oral route 5 day every 28 day ( 6 cycle ) ( 40MG/M² , 30 MG/M² patient 75 year old ) . The primary objective compare efficacy ( response rate ) Chlorambucil Fludarabine previously untreated patient . The secondary objective duration response , improvement hematological parameter , toxicity , quality life , event free survival overall survival .</brief_summary>
	<brief_title>Trial Comparing Chlorambucil Fludarabine Patients With Advanced Waldenström Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Established diagnosis Waldenström macroglobulinemia ( 2nd Workshop Waldenstrom 's macroglobulinemia ) Lymphoplasmacytic lymphoma Splenic Marginal Zone Lymphoma , need treatment Life expectancy &gt; 6 month Creatinine &lt; 200 µmol/l SGPT SGOT &lt; 2x ULN A negative direct Coombs test Written inform consent Past chemotherapy/radiotherapy/immunotherapy prior study Waldenström macroglobulinemia Previous malignancy le 5 year ago except carcinoma situ cervix nonmelanoma skin cancer Positive HIV serology Active Hepatitis B C Lactation/pregnancy Impossible good compliance study protocol Active infection control Psychological condition hamper understand study Transformation large B cell lymphoma Peripheral neuropathy &gt; grade II</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Waldenström Macroglobulinemia</keyword>
	<keyword>Lymphoplasmacytic lymphoma</keyword>
	<keyword>Splenic Marginal Zone Lymphoma</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Chlorambucil</keyword>
</DOC>